Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and … — Gut microbes (2026)

Identificação

• PMID: 42343233
• DOI: 10.1080/19490976.2026.2690689
• Autores: Peter Suenaert, Anneleen Segers, Leen Rymenans, Hélène Devroye, Janne Marie Moll, Patrice D Cani
• Revista: Gut microbes

Resumo clínico (PT)

Resumo em português pendente de revisão editorial. Configure OPENAI_API_KEY para geração automática ou edite manualmente.

Abstract (original)

Pasteurized Akkermansia muciniphila MucT was found to improve barrier function in preclinical models and a proof-of-concept study in obese and prediabetic adults. Here, we describe the results of a double-blind placebo-controlled multicenter (Ireland and Germany) trial in 142 adults with metabolic syndrome, with or without prediabetes. The primary endpoint of whole-body insulin sensitivity (Matsuda index) did not differ after 4-months of daily administration of capsules containing 30 billion cells of pasteurized A. muciniphila MucT compared to placebo in the intention-to-treat subjects. Subsequent exploratory analyses showed that 3-months intake of pasteurized A. muciniphila MucT already improved HOMA-based hepatic insulin sensitivity in prediabetic (12%; p = 0.05) and 63-y-or-older-age subgroups ( p = 0.05) while increasing post-OGTT excursion of the insulinotropic hormone glucagon-like peptide 1 (GLP-1) over placebo ( p Akkermansia gene counts experienced significant health improvements and GLP-1 excursion after 3-months of treatment with pasteurized A. muciniphila MucT over the placebo. These benefits included improved insulin sensitivity (as shown by Matsuda and HOMA-S indices) and GLP-1 excursion (post-OGTT) ( p p = 0.06) and decreased trunk fat ( p A. muciniphila MucT has the potential to improve health markers in overweight or obese normo- or dysglycemic adults with the most significant improvements in subjects with low baseline intestinal Akkermansia levels, who are apparently truly in need of this intervention. Clinical trial registration no.: NCT05114018 clinicaltrials.gov.